Quotient Bioresearch is selling its Bioanalytical Sciences division to LGC. The acquiring firm says the deal will enable it to provide an enhanced range of products and services to the pharmaceutical sector including bioanalysis, materials science, and reference materials.
The firms have agreed to collaborate as preferred partners to provide bioanalytical sciences services. This will enable clients to continue to receive early development services offered by the Quotient group including clinical trials, metabolism, and radiolabelling.
Quotient Bioanalytical Sciences provides bioanalytical services across the fields of small molecules, biomarkers, biopharmaceuticals, and microbiological testing to customers in the pharmaceutical and biotechnology sectors.
“LGC’s focus on complex analytical chemistry, high-quality science, and service delivery make them a natural home for our business,” says Dr. Steve Pleasance, managing director of Quotient Bioanalytical Sciences. “Both our organizations have reputations built upon quality and innovation, and LGC’s global presence will help support the continued growth of services to our customers.”
Quotient Bioanalytical Sciences is based at Fordham, Cambridgeshire. This transaction follows the sale two years ago by Quotient to LGC of HFL Sport Science, which is also based at the Fordham site.
LGC has been busy with M&A activity lately. Last month, the firm acquired the trade and assets of Bio Senate, a supplier of microbiology proficiency testing and reference materials based in Bury, U.K. Just over a year ago, the company acquired Industrial Analytical of South Africa, which it says was the single largest supplier of certified reference materials on the southern African continent. Also in 2011, LGC picked up KBioscience for its expertise in genotyping services.